{"id":15139,"date":"2017-11-21T08:00:01","date_gmt":"2017-11-21T13:00:01","guid":{"rendered":"https:\/\/www.terrybryant.com\/?p=15139"},"modified":"2023-09-23T04:16:59","modified_gmt":"2023-09-23T09:16:59","slug":"benicar-improper-labeling-lawsuit-settlement-failure-warn","status":"publish","type":"post","link":"https:\/\/www.terrybryant.com\/blogs\/benicar-improper-labeling-lawsuit","title":{"rendered":"Benicar Improper Labeling Lawsuit Settlement and \u201cFailure to Warn\u201d"},"content":{"rendered":"

\t\t\t\tIn late July 2017, Daiichi Sankyo agreed to pay up to $300 million in more than 2,000 U.S. cases surrounding the Japanese drugmaker\u2019s failure to warn that its blood pressure medication, Benicar, can cause gastrointestinal (GI) illness.<\/p>

<\/div>\n

The first of these lawsuits was filed in early 2014, shortly after the U.S. Food and Drug Administration (FDA) ordered the manufacturer to make changes to its improperly labeled products that should have warned of the drug\u2019s risks of severe GI side-effects<\/a>. The cases filed separately in many U.S. states were eventually consolidated in a multidistrict litigation (MDL) in a New Jersey federal court.<\/p>\n

Fifteen test cases in the MDL called “bellwethers” \u2013 cases which attorneys on both sides use to weigh the effectiveness of their respective arguments \u2013 were entered into the court\u2019s docket for the fall of 2017. But before any of them went to trial, Benicar\u2019s manufacturer, Daiichi Sankyo, began settling with the plaintiffs from which the 15 bellwethers were selected.<\/p>\n

Injured victims alleged that until a decade after the drugs hit the market, Benicar, along with its affiliate drugs Benicar HCT, Azor, and Tribenzor, carried no labels or literature that warned of the GI side-effects, which included:<\/p>\n